| Cancer and immunotherapy |
breast cancer |
in vivo and in vitro
|
injectable thermosensitive
photothermal-network hydrogel |
well-controlled drug delivery,
photothermal anti-cancer effect |
(77b) |
| |
CT-26 carcinoma and 4T1 breast tumor in mice |
in vivo |
alginate-collagen thermosensitive
hydrogel/indocyanine green/polycytidylic
acid |
anticancer and metastatic properties |
(78) |
| |
glioblastoma multiforme |
in vivo (mouse) |
zinc 2-methylimidazole/mitoxantrone/hydrogel |
inducing immune tumor cell death, indoleamine 2,3-dioxygenase-1
suppression |
(79) |
| Tissue engineering |
women with knee osteoarthritis |
double-blind RCT |
pequi
oil/carbopol/hydrogel |
no cytotoxicity |
(82) |
| biocompatibility |
| not irritating |
| knee extensor and flexor muscle strength ↑ |
| |
rat models |
in vivo |
rat bone marrow mesenchymal stem cell (rBMSCs)
/HA/chitosan/collagen thermosensitive hydrogel |
biocompatibility |
(83) |
| well biomimic behavior |
| good mechanical properties |
| |
rat models with femoral defects |
in vivo |
alginate/sericin/graphene oxide/hydrogel |
inflammation
inhibition ↑ |
(84) |
| distal femur defects repair speed ↑ |
| osteogenic differentiation ↑ |
| |
cancellous bone defect |
in vivo |
BMSCs/Gelatin methacrylamide photocross-linked hydrogel |
nontoxic |
(86) |
| |
|
|
|
nonimmunogenic |
|
| |
|
|
|
biodegradable |
|
| |
|
|
|
high BMSC loading
capacity proliferation |
|
| |
rat models with calvarium defect |
in vitro and in vivo
|
MSC/nanohydroxyapatite/nano
silicate/gelatin-methacryloyl hydrogel |
cellular viability
↑, spreading behavior ↑, cell
proliferation ↑ |
(87) |
| |
endometrial ECM (proliferation) |
in vitro and in vivo (mice) |
collagen, elastin, and glycosaminoglycans
hydrogels/endoECM |
endoECM proliferation ↑ |
(88) |
| cytocompatibility ↑ |
| |
diabetic wound treatment |
in vitro and in vivo
|
HA methacrylate/phenylboronic
acid/catechin hydrogel |
glucose-responsive catechin release,
biocompatibility, skin
tissue structure biomimicry angiogenesis ↑, inflammatory response
↓ |
(90) |
| |
focal full-thickness cartilage defected patients |
CT |
hydrogel-based autologous
articular chondrocytes |
knee osteoarthritis outcome score
(KOOS) ↑ |
(91) |
| biocompatibility ↑ |
| |
spinal
cord injury repair |
in vivo and in vitro
|
umbilical
cord mesenchymal stem cells/fibroblast
growth factor/extracellular matrix/heparin-poloxamer |
cell apoptosis ↓ |
(92) |
| mitochondrial function
↑ |
|
| |
diabetic wound |
in vivo and in vitro
|
human umbilical vein endothelial cells/Protamine,
calcium alginate, hyaluronan |
bacterial chronic inflammation |
(93) |
| accelerating wound healing |
| angiogenesis ↑ |
| Cardiovascular tissue |
chronic ischemic heart disease |
RCT |
injectable collagen/human umbilical cord-derived
mesenchymal stromal cell |
ejection fraction ↑ |
(95) |
| infarct size ↑ |
| safety |
| |
cardiac repair |
in
vivo |
induced pluripotent stem
cell-derived cardiac
progenitors (iPS-CPCs) /ECM, Methacrylic anhydride, HA hydrogel |
iPS-CPCs cardiac differentiation ↑ |
(96) |
| cardiac repair exosome delivery ↑ |
| cardiac functions↑ |
| |
vascularization inducing |
in vivo and in vitro
|
polysaccharide chitosan/sodium β-glycerophosphate/gelatin/loaded
with VEGF and stromal cell-derived factor-1 |
inducing
MSCs and endothelial cells to differentiate into vessels |
(97) |
| |
biocompatibility ↑ |
| selective drug release |
| |
myocardial infarction |
in vivo |
dendritic cell-derived exosomes/alginate hydrogel |
regulatory
T cells activity ↑ |
(98) |
| macrophage polarization ↑ |
| cardial
function ↑ |
| |
myocardial infarction |
in vivo |
Tβ4-exosomes/GelMA/PEGDA
hydrogel |
coronary collateralization ↑ |
(99) |
| angiogenic capacity ↑ |
| |
myocardial infarction-ischemia |
in vivo |
UCMSCs/epoxy macromer/thiolated hyaluronic |
tissue repair
↑ |
(100) |
| angiogenesis ↑ |
| biocompatibility ↑ |
| Gene and cell therapy |
osteoarthritis |
in
vivo |
phenylalanine-modified generation
5 polyamidoamine/microRNA-140 |
gene transfection efficacy
↑ |
(101) |
| long-term bioactivity
↑ |
| endocytosis ↑ |
| |
breast cancer |
in vivo and in vitro
|
RNA-triple-helix hydrogel (miRNA-221/miRNA-205( |
selectivity uptake ↑ |
(102) |
| miRNA expression control ↑ |
| |
allergic rhinitis |
ex vivo and in vitro
|
sodium glycerophosphate/chitosan/PEG–PLA/miRNA-146a |
nasal mucosal adhesion ↑ |
(103) |
| RNA delivery stability ↑ |
| release
time ↑ |
| |
subcutaneous human medulloblastoma |
in vivo |
hydroxypropyl
methylcellulose/PEG–PLA NPs/CAR-T
cells/ |
inflammatory niche generating |
(104) |
| CAR-T cell treatment efficacy ↑ |
| long-term viability and activation of T cells ↑ |
| Neural tissue |
spinal cord injury |
in vivo |
peptide-modified
HA hydrogel/mesenchymal stem
cell derived exosomes |
nerve recovery ↑ |
(105) |
| inflammation ↓ |
| sustainable release |
